BioSpace News Archive

Business

Noxilizer Leaves Baltimore BioPark for New Arundel HQ

The company inked a lease for 10,481 square feet of office space located off of Route 100 in Hanover.

January 10, 2018
·
1 min read
New Venture Fund Banks $102M for Biotech and Medical Device Development

Truffle Capital, founded in 2001 and based in Paris, is a venture capital firm that focuses on supporting start-ups in in life sciences and IT.

January 10, 2018
·
3 min read
Policy

Ambitious Bluebird Seeks Three Drug Approvals by 2019

As yet, the company has no products on the market, so the applications, if approved, would mark the company’s shift into a commercial company.

January 10, 2018
·
3 min read
·
Mark Terry
Deals

Nestle Emerges as the Frontrunner for Merck KGaA’s $5B Consumer Health Biz

Nestle submitted the highest offer and Merck was likely to select a winner during the first quarter, but might also choose not to sell the assets after all.

January 10, 2018
·
1 min read
Policy

Forensic Exam Shows Pattern in 4 Deaths of Sanofi Dengue Vaccine Recipients

Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine.

January 10, 2018
·
1 min read
Policy

3SBio Approved to Market Once-Weekly Type 2 Diabetes Treatment in China

3SBio reported the CFDA formally approved Bydureon, its once-weekly Glucagon-like peptide-1 receptor agonist for type 2 diabetes treatment.

January 10, 2018
·
1 min read
Deals

Fosun Pays $18M for China Rights to Novel Parkinson’s Disease Drug

Fosun Pharma acquired China rights to market a novel treatment for Parkinson’s disease from Bial in an $18M agreement. BIAL developed Ongentys as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors.

January 10, 2018
·
1 min read
FDA

PTC Therapeutics CEO to Fight for DMD Therapy, Pushes Forward with SMA Treatment

The company believes the Translarna data is compelling and pointed to the success the drug is having in Europe.

January 10, 2018
·
3 min read
·
Alex Keown